British drugmaker GSK plc has announced plans to invest $30 billion across the United States (US) in research and development and supply chain infrastructure over the next five years.
This includes a new $1.2 billion investment in advanced manufacturing facilities and artificial intelligence (AI) and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories in the United States.
These investments build on GSK’s strong innovation and manufacturing footprint and capabilities in the United States today, developing and making products in the United States for the United States.
The $1.2 billion investment includes:
The $30 billion investment in the US includes capital investments across GSK’s U.S. supply chain, as well as increased investment in R&D drug discovery and development and clinical trial activity, with the US expected to rank first globally for the number of studies, sites and clinical trials participants conducted by GSK over the next five years.
This announcement means GSK has committed new investments of approximately $2 billion in US manufacturing over the last 12 months. In October 2024, construction began of a new $800 million facility at GSK’s Marietta, Pennsylvania site, doubling the size and capacity of the site. These new manufacturing investments will create hundreds of highly skilled jobs (in addition to construction jobs), building upon GSK’s approximately 15,000 strong US workforce.
